| Q38491230 | 13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia |
| Q101118296 | SF3B1-mutated chronic lymphocytic leukemia shows evidence of NOTCH1 pathway activation including CD20 downregulation |
| Q92022521 | A B-cell receptor-related gene signature predicts response to ibrutinib treatment in mantle cell lymphoma cell lines |
| Q52730895 | A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the Fondazione Italiana Linfomi MCL-0208 trial. |
| Q89658710 | A Novel Comprehensive Clinical Stratification Model to Refine Prognosis of Glioblastoma Patients Undergoing Surgical Resection |
| Q90748872 | A Pan-Cancer Approach to Predict Responsiveness to Immune Checkpoint Inhibitors by Machine Learning |
| Q91230219 | A TGF-β associated genetic score to define prognosis and platinum sensitivity in advanced epithelial ovarian cancer |
| Q59211799 | A scoring system based on the expression of six surface molecules allows the identification of three prognostic risk groups in B-cell chronic lymphocytic leukemia |
| Q60358240 | ARHGDIA, a mutant TP53-associated Rho GDP dissociation inhibitor, is over-expressed in gene expression profiles ofTP53disrupted chronic lymphocytic leukaemia cells |
| Q46851031 | Activation-induced cytidine deaminase and CD38 expression in B-cell chronic lymphocytic leukemia. |
| Q47339225 | Analysis of IgV gene mutations in B cell chronic lymphocytic leukaemia according to antigen-driven selection identifies subgroups with different prognosis and usage of the canonical somatic hypermutation machinery |
| Q55044243 | Are surrogates of IGHV gene mutational status useful in B-cell chronic lymphocytic leukemia? The example of Septin-10. |
| Q51025698 | Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia. |
| Q37837955 | B-cell receptor, clinical course and prognosis in chronic lymphocytic leukaemia: the growing saga of the IGHV3 subgroup gene usage |
| Q64124611 | Biallelic BIRC3 inactivation in chronic lymphocytic leukaemia patients with 11q deletion identifies a subgroup with very aggressive disease |
| Q44276636 | CD38/CD31, the CCL3 and CCL4 chemokines, and CD49d/vascular cell adhesion molecule-1 are interchained by sequential events sustaining chronic lymphocytic leukemia cell survival |
| Q46467811 | CD49d expression identifies a chronic-lymphocytic leukemia subset with high levels of mobilized circulating CD34(+) hemopoietic progenitors cells. |
| Q60358511 | CD49d in B-cell chronic lymphocytic leukemia: correlated expression with CD38 and prognostic relevance |
| Q58319764 | CD49d is overexpressed by trisomy 12 chronic lymphocytic leukemia cells: evidence for a methylation-dependent regulation mechanism |
| Q40784167 | CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia. |
| Q35717883 | CD69 is independently prognostic in chronic lymphocytic leukemia: a comprehensive clinical and biological profiling study. |
| Q36420752 | Clinical significance of bax/bcl-2 ratio in chronic lymphocytic leukemia |
| Q43558209 | Clinical significance of c.7544-7545 delCT NOTCH1 mutation in chronic lymphocytic leukaemia |
| Q58001030 | Comprehensive characterization of IGHV3-21-expressing B-cell chronic lymphocytic leukemia: an Italian multicenter study |
| Q34461989 | Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application. |
| Q45762178 | Exposure of B cell chronic lymphocytic leukemia (B-CLL) cells to nutlin-3 induces a characteristic gene expression profile, which correlates with nutlin-3-mediated cytotoxicity. |
| Q58000969 | Expression of Mutated IGHV3-23 Genes in Chronic Lymphocytic Leukemia Identifies a Disease Subset with Peculiar Clinical and Biological Features |
| Q62926878 | Expression of the transcribed ultraconserved region 70 and the related long non-coding RNA AC092652.2-202 has prognostic value in Chronic Lymphocytic Leukaemia |
| Q38925105 | Functional and Clinical Significance of the Integrin Alpha Chain CD49d Expression in Chronic Lymphocytic Leukemia |
| Q48307279 | Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia |
| Q96682110 | Glucose Metabolism and Oxidative Stress in Hepatocellular Carcinoma: Role and Possible Implications in Novel Therapeutic Strategies |
| Q91753700 | HIF-1α is over-expressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia |
| Q58000974 | IGHD3-3fails to behave as unfavourable prognostic marker in chronic lymphocytic leukaemia |
| Q52993622 | Ibrutinib-naïve chronic lymphocytic leukemia lacks Bruton tyrosine kinase mutations associated with treatment resistance. |
| Q53640307 | Immunophenotypic characterization of IgVH3-72 B-cell chronic lymphocytic leukaemia (B-CLL). |
| Q28394721 | Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia |
| Q37588785 | Intrinsic and extrinsic factors influencing the clinical course of B-cell chronic lymphocytic leukemia: prognostic markers with pathogenetic relevance |
| Q92372468 | KRAS, NRAS, and BRAF mutations are highly enriched in trisomy 12 chronic lymphocytic leukemia and are associated with shorter treatment-free survival |
| Q95660385 | Loss of Spry1 reduces growth of BRAFV600-mutant cutaneous melanoma and improves response to targeted therapy |
| Q47634173 | Low-dose radiotherapy in diffuse large B-cell lymphoma. |
| Q43052729 | MDM4 (MDMX) is overexpressed in chronic lymphocytic leukaemia (CLL) and marks a subset of p53wild-type CLL with a poor cytotoxic response to Nutlin-3. |
| Q38010501 | Microenvironmental interactions in chronic lymphocytic leukemia: hints for pathogenesis and identification of targets for rational therapy |
| Q38232480 | Microenvironmental interactions in chronic lymphocytic leukemia: the master role of CD49d. |
| Q58001001 | Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study |
| Q54387895 | Molecular and clinical features of chronic lymphocytic leukemia with stereotyped B-cell receptors in a Ukrainian cohort. |
| Q44752987 | Mutational status of IGHV is the most reliable prognostic marker in trisomy 12 chronic lymphocytic leukemia. |
| Q43518448 | Mutational status of IgV(H) genes in B-cell chronic lymphocytic leukemia and prognosis: percent mutations or antigen-driven selection? |
| Q80799075 | Mutational status of IgVH genes consistent with antigen-driven selection but not percent of mutations has prognostic impact in B-cell chronic lymphocytic leukemia |
| Q60358020 | Mutations in the 3′ untranslated region of NOTCH1 are associated with low CD20 expression levels chronic lymphocytic leukemia |
| Q48140340 | NOTCH1 mutational status in chronic lymphocytic leukaemia: clinical relevance of subclonal mutations and mutation types. |
| Q52931736 | NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: evidence for a NOTCH1 mutation-driven epigenetic dysregulation. |
| Q54345184 | NOTCH1 mutations identify a chronic lymphocytic leukemia patient subset with worse prognosis in the setting of a rituximab-based induction and consolidation treatment. |
| Q92344153 | New Insight into Therapies Targeting Angiogenesis in Hepatocellular Carcinoma |
| Q94550470 | New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma |
| Q92589900 | Novel immunotherapeutic approaches for hepatocellular carcinoma treatment |
| Q52930409 | Persistent CD49d engagement in circulating CLL cells: a role for blood-borne ligands? |
| Q38945688 | Potential therapeutic role of antagomiR17 for the treatment of chronic lymphocytic leukemia |
| Q33758834 | Prognostic impact of ZAP-70 expression in chronic lymphocytic leukemia: mean fluorescence intensity T/B ratio versus percentage of positive cells |
| Q60358460 | Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia |
| Q45191343 | Signature of B-CLL with different prognosis by Shrunken centroids of surface antigen expression profiling |
| Q40366836 | Surface-antigen expression profiling (SEP) in B-cell chronic lymphocytic leukemia (B-CLL): Identification of markers with prognostic relevance |
| Q42702972 | Surface-antigen expression profiling of B cell chronic lymphocytic leukemia: from the signature of specific disease subsets to the identification of markers with prognostic relevance |
| Q39404177 | The CD49d/CD29 complex is physically and functionally associated with CD38 in B-cell chronic lymphocytic leukemia cells. |
| Q90411487 | The Dual Role of the Liver in Nanomedicine as an Actor in the Elimination of Nanostructures or a Therapeutic Target |
| Q53014079 | The Krüppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma. |
| Q26797469 | The MYC/miR-17-92 axis in lymphoproliferative disorders: A common pathway with therapeutic potential |
| Q104480247 | The Molecular and Microenvironmental Landscape of Glioblastomas: Implications for the Novel Treatment Choices |
| Q36326340 | The SIRT1/TP53 axis is activated upon B-cell receptor triggering via miR-132 up-regulation in chronic lymphocytic leukemia cells. |
| Q43257115 | The expression levels of the pro-apoptotic XAF-1 gene modulate the cytotoxic response to Nutlin-3 in B chronic lymphocytic leukemia |
| Q54323506 | The miR-17∼92 family regulates the response to Toll-like receptor 9 triggering of CLL cells with unmutated IGHV genes. |
| Q38851329 | Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia. |
| Q60358588 | ZAP-70 expression in B-cell chronic lymphocytic leukemia: Evaluation by external (isotypic) or internal (T/NK cells) controls and correlation with IgVH mutations |